Phase II study of etoposide for carcinoma of the prostate.
Journal Article (Clinical Trial;Journal Article)
The treatment of prostate carcinoma with the epipodophyllotoxin derivative etoposide was studied in a multi-institutional phase II trial. An iv dose schedule of 130 mg/m2 daily for 3 days every 3 weeks was utilized. A total of 36 patients were evaluable; the observed total response was 3%. Moderate toxicity (predominantly myelosuppression) was seen utilizing this treatment schedule. It is concluded that etoposide possesses little single-agent therapeutic activity for prostate carcinoma.
- Walther, PJ; Williams, SD; Troner, M; Greco, FA; Birch, R; Einhorn, LH
- June 1986
Volume / Issue
- 70 / 6
Start / End Page
- 771 - 772
International Standard Serial Number (ISSN)
- United States